14-day Premium Trial Subscription Sign Up For FreeGet Free

$12.02 (-1.23%)

Volume: 824k

Closed: Nov 29, 2021

Hollow Logo Score: 4.114

FibroGen Stock Forecast

$12.02 (-1.23%)

Volume: 824k

Closed: Nov 29, 2021

Score Hollow Logo 4.114

FibroGen Stock Forecast NASDAQ:FGEN

Price Target and Analyst Ratings

Most Recent Rating

On Sep 22, 2021 "The Goldman Sachs Group" gave "$16.00 - $11.00" rating for FGEN. The price target was changed from $11.24 to 0.3%.

Last 30 Days

Historical Ratings

Date Rating Action Authority Current Price Target Price
2021-09-22 $16.00 - $11.00 Downgraded by The Goldman Sachs Group $10.18 $11.24→0.3%
2021-08-20 Upgraded by Raymond James $12.11 $11.47→4.9%
2021-08-11 $16.00 - $22.00 Target Raised by The Goldman Sachs Group $12.43 $12.43→5.8%
2021-08-10 $35.00 - $30.00 Target Lowered by SVB Leerink $13.19 $13.79+0.4%
2021-07-16 $29.00 Downgraded by Bank of America $14.35 $24.84+1.0%
2021-07-16 $32.00 - $18.00 Target Lowered by Mizuho $14.35 $24.84+1.0%
2021-07-16 $55.00 - $29.00 Downgraded by Stifel Nicolaus $14.35 $24.84+1.0%
2021-07-16 $56.00 - $35.00 Reiterated by SVB Leerink $14.35 $14.40→42.0%
2021-07-16 $21.00 - $16.00 Target Lowered by Cowen $14.35 $14.40→42.0%
2021-06-28 $29.00 - $32.00 Target Raised by Mizuho $27.64 $26.47+0.2%
2021-06-28 Positive - Neutral Target Raised by Mizuho $27.64 $29.00 → $32.00
2021-04-13 Outperform Target Lowered by SVB Leerink $19.73 $64.00 → $56.00
2021-04-13 Buy - Neutral Reiterated by Mizuho $19.73 $29.00
2021-04-13 Buy - Neutral Reiterated by HC Wainwright $19.73
2021-04-13 Underweight - Neutral Upgraded by JPMorgan Chase & Co. $19.73
2021-04-07 Buy - Neutral Downgraded by HC Wainwright $19.74
2021-04-07 Buy - Neutral Downgraded by Mizuho $19.74 $72.00 → $29.00
2021-04-07 Sell Reiterated by Raymond James $19.74
2021-04-07 Outperform Target Lowered by SVB Leerink $19.74 $64.00 → $56.00
2021-04-07 Neutral Upgraded by JPMorgan Chase & Co. $19.74
2021-03-31 Neutral - Buy Upgraded by Bank of America $34.71 $47.00
2021-03-08 Buy - Hold Reiterated by Jefferies Financial Group $33.37 $75.00 → $45.00
2021-03-08 Outperform Target Lowered by SVB Leerink $33.37 $91.00 → $64.00
2021-03-02 Outperform Target Lowered by SVB Leerink $38.07 $91.00 → $64.00
2021-03-02 Buy - Hold Downgraded by Jefferies Financial Group $38.07 $75.00 → $45.00
2021-02-01 Buy Initiated by HC Wainwright $49.62 $58.00
2020-11-06 Outperform Target Raised by SVB Leerink $41.28 $90.00 → $92.00
2020-10-26 Underperform Initiated by Raymond James $39.96
2020-09-08 Outperform Target Raised by SVB Leerink $42.16 $84.00 → $90.00
2020-08-07 Outperform Target Raised by SVB Leerink $44.20 $80.00 → $84.00
2020-05-11 Buy Reiterated by Mizuho $39.61
2020-05-08 Outperform Target Lowered by SVB Leerink $36.42 $85.00 → $80.00
2020-05-01 Market Perform Initiated by Cowen $34.98 $40.00
2020-04-27 Neutral Initiated by Bank of America $39.90 $45.00

FGEN Stock Trend

The stock lies in the middle of a very wide and weak rising trend in the short term and a further rise within the trend is signaled.

Given the current short-term trend, the stock is expected to rise 7.25% during the next 3 months and, with a 90% probability hold a price between $11.25 and $14.33 at the end of this 3-month period.

Data

Date Bottom Mid Top
2021-12-01 $10.50 $11.94 $13.38
2021-12-02 $10.52 $11.96 $13.39
2021-12-03 $10.53 $11.97 $13.41
2021-12-06 $10.55 $11.98 $13.42
2021-12-07 $10.56 $12.00 $13.44
2021-12-08 $10.58 $12.01 $13.45
2021-12-09 $10.59 $12.03 $13.47
2021-12-10 $10.60 $12.04 $13.48
2021-12-13 $10.62 $12.06 $13.49
2021-12-14 $10.63 $12.07 $13.51
2021-12-15 $10.65 $12.09 $13.52
2021-12-16 $10.66 $12.10 $13.54
2021-12-17 $10.68 $12.11 $13.55
2021-12-20 $10.69 $12.13 $13.57
2021-12-21 $10.70 $12.14 $13.58
2021-12-22 $10.72 $12.16 $13.59
2021-12-23 $10.73 $12.17 $13.61
2021-12-27 $10.75 $12.19 $13.62
2021-12-28 $10.76 $12.20 $13.64
2021-12-29 $10.78 $12.21 $13.65
2021-12-30 $10.79 $12.23 $13.67
2021-12-31 $10.81 $12.24 $13.68
2022-01-03 $10.82 $12.26 $13.70
2022-01-04 $10.83 $12.27 $13.71
2022-01-05 $10.85 $12.29 $13.72
2022-01-06 $10.86 $12.30 $13.74
2022-01-07 $10.88 $12.31 $13.75
2022-01-10 $10.89 $12.33 $13.77
2022-01-11 $10.91 $12.34 $13.78
2022-01-12 $10.92 $12.36 $13.80

About FibroGen

FibroGen FibroGen, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs. It is developing roxadustat, or FG-4592, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; FG-3019, a monoclonal antibody in Phase II clinical development ... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!

StockInvest.usJoin 100 000+ Happy Subscribers

Don't miss out on the runners!

Get The StockInvest.Us Newsletter

StockInvest.usStock Podcast

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT